Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 790 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Therapy for head and neck cancer Clear all
Not listed No phase listed Observational

A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers

NCT01936376
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck

NCT00938080
View directory record Official record
Conditions
Oral Mucositis
Interventions
AG013, Placebo
Biological · Other
Lead sponsor
ActoGeniX N.V.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

NCT04291079
View directory record Official record
Conditions
Cancer
Interventions
SRK-181, anti-PD-(L)1 antibody therapy
Biological
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Fullerton, California • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Phase 2 Interventional

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

NCT01467115
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel
Radiation · Drug · Biological
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 16, 2026, 2:08 AM EDT
Recruiting Phase 2 Interventional

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

NCT04988074
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma
Interventions
Cemiplimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 16, 2026, 2:08 AM EDT
Suspended Phase 2Phase 3 Interventional

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

NCT05050162
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
1,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
361
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 264 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

NCT03829722
View directory record Official record
Conditions
Oropharynx Squamous Cell Carcinoma
Interventions
Nivolumab, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

NCT03978689
View directory record Official record
Conditions
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
Interventions
CUE-101, KEYTRUDA®, Pembrolizumab
Drug
Lead sponsor
Cue Biopharma
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
17
States / cities
Tucson, Arizona • Palo Alto, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 16, 2026, 2:08 AM EDT
Completed No phase listed Observational

Wound Complications in Head and Neck Surgery

NCT03134976
View directory record Official record
Conditions
Hypothyroidism; Surgery, Head and Neck Cancer, Wound Heal, Laryngeal Cancer, Laryngeal Fistula
Interventions
Levothyroxine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 16, 2026, 2:08 AM EDT
Completed No phase listed Observational

3M Cavilon Advanced Skin Protectant for the Prophylaxis of Radiation Dermatitis

NCT03546803
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
3M™ Cavilon™ Advanced Skin Protectant
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Phase 2 Interventional

Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer

NCT00005088
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
0 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
239
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 182 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 16, 2026, 2:08 AM EDT
Recruiting Phase 1 Interventional

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

NCT07156227
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Sinonasal Cancer AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Sinonasal Cancer AJCC v8, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hypopharyngeal Squamous Cell Carcinoma, Unresectable Laryngeal Squamous Cell Carcinoma, Unresectable Oral Cavity Squamous Cell Carcinoma, Unresectable Oropharyngeal Squamous Cell Carcinoma, Unresectable Paranasal Sinus Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Camonsertib, Computed Tomography, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
3
States / cities
Duarte, California • Irvine, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00656513
View directory record Official record
Conditions
Head and Neck Cancer, Xerostomia
Interventions
Pilocarpine, ALTENS
Drug · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
16
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 16, 2026, 2:08 AM EDT
Terminated Phase 2 Interventional Results available

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

NCT00591149
View directory record Official record
Conditions
Head and Neck Cancer, Carcinoma, Squamous
Interventions
Oxaliplatin, Docetaxel, Cetuximab
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 16, 2026, 2:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spousal Support in Head and Neck Cancer

NCT00824252
View directory record Official record
Conditions
Head And Neck Cancer
Interventions
Questionnaires & Study Visit
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer

NCT00851253
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
stereotactic radiosurgery
Radiation
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Not applicable Interventional Results available

Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients

NCT00606294
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
fluorine-18-labeled fluoro-misonidazole (18F-FMISO), 18F-FMISO PET scan, MRI, FDG PET/CT scan
Radiation · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2023
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

NCT01581970
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Cyclophosphamide, Cetuximab
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis

NCT02399228
View directory record Official record
Conditions
Oral Mucositis
Interventions
0.25% EISO mouth rinse
Drug
Lead sponsor
Santalis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers

NCT01163487
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Cancers
Interventions
Dichloroacetate, EF5
Drug · Device
Lead sponsor
Daniel T. Chang
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer

NCT00570232
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Erlotinib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 16, 2026, 2:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

NCT04193293
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Duvelisib, Pembrolizumab
Drug · Biological
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 16, 2026, 2:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer

NCT00581971
View directory record Official record
Conditions
Cancer
Interventions
celecoxib, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 16, 2026, 2:08 AM EDT
Recruiting No phase listed Observational

DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies

NCT05671887
View directory record Official record
Conditions
Lung Cancer, Bilateral Cancer, Lung Transplant
Interventions
Double Lung Transplantation
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 75 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 16, 2026, 2:08 AM EDT